The primary objective of this research work is to develop a serum bactericidal assay (SBA) for the quantification of bactericidal antibodies in human serum for P.aeruginosa (pSBA). Whole cell antigens (Heat and formalin inactivated) were generated from clinical isolates. It was screened for Anti-pseudomonas antibodies (IgG) using ELISA technique. An increased sero-reactivity with heat killed preparation 54-63% were observed than formalin killed. It may be due to the presence of different epitopes in heat& formalin inactivated antigen. ELISA positive sera were pSBA positive. No sero-cross reactivity in pSBA. No major variations in pSBAtitre with different bacterial inoculum tested. pSBA antibody driven with no interference with endogenous complement. This study demonstrated Anti-pseudomonas functional activity in human serum.
Introduction
Pseudomonas is the most important genus in the order Pseudomonadales, the family Pseudomonaceae. Pseudomonas aeruginosa is a ubiquitous and remarkably versatile bacterium (Tidy, 2014) . These bacteria are straight or slightly curved rods, 0.5 -1.0 m by 1.5 -5.0 m in size and are motile by one or several polar flagella. Mucoid form (capsule) is an adaptation mechanism of P. aeruginosa for surviving in aquatic environments by forming a polysaccharide net/biofilm rich in alginate (Pedersen et al., 1990)
Virulence Factors
Pseudomonas has a number of virulence factors (Lyczak et al., 2000) , which includes:  Capsule, exotoxin A and various proteases that facilitated immune evasion, tissue and cellular damage for pathogenicity  Pyocyanine -P. aeruginosa synthesizes a characteristic blue redox-active secondary metabolite, that is chloroform-soluble and a member of the tricyclic compounds "phenazine" called pyocyanine which is chemically, hydroxy5-methyl-phenazine (van delden 2004)
Epidemiology
P. aeruginosa flourishes in different ecological environments including soil, river, waste water, plant, animal and human. This Gram-negative bacteria lives in water and soil and acts as an opportunistic pathogen in humans and plants (Jamileh et al., 2012) . Many advances in understanding the physiology and biochemistry of this organism and microbes in general have been borne off these studies. The genome of P. aeruginosa has an unusually large number of genes for catabolism, nutrient transport, the efflux of organic molecules, and metabolic regulation. This may explain its ability to grow in many environments and resist antibiotics (Arancibia et al., 2002).
In vitro Serology
The serum bactericidal test (SBT) is a modification of the broth dilution method that measures the bactericidal activity of the patient's serum during antimicrobial therapy against the bacterial pathogen isolated from that patient. It is one of the few in vitro tests performed in the clinical microbiology laboratory that incorporates the interaction of the pathogen, the antimicrobial agent, and the patient. Although the use of such a test for assessing the bactericidal activity in a patient's serum has been widely used for 40 years, its performance, results, and interpretation have been subject to question and controversy. The bactericidal effect of normal serum on gram-negative bacteria was investigated with the objective of determining whether this antibody-complement reaction could be used for the measurement of antibody. The major variables affecting the outcome of this complement dependent reaction were explored systematically to establish the test conditions in which specific antibody was the limiting factor (Stratton 1988 ).
Review of Literature
The aim of this study is to develop a serum bactericidal assay (SBA) to evaluate the ability of the serum antibodies to kill P. aeruginosa by direct augmentation of complement cascade. On reviewing the literature, serum bactericidal assay model is popularly used as a platform to quantify the minimum Inhibitory concentration of antibiotics as SBT rather than SBA. Even though Gram negative bacterium owing to their cell complexity are predominantly killed by complement cascade and less through opsonophagocytosis, some strains of serum non-sensitive Pseudomonas strains tends to interfere with complement components. Hence, we found limited literatures pertaining to the development of SBA for pseudomonas.
Historical review of the SBT
Of the laboratory methods for assessing bactericidal activity, it is not surprising that the SBT has received the most attention. Tests to estimate the bactericidal activity of blood These guidelines review aspects of bactericidal testing and the SBT which require standardization. The use of these guidelines through the National Committee for Clinical Laboratory Standards consensus mechanism should allow agreement about standardized methods. This will then enable the appropriate prospective clinical trials to be done to provide a rational data base for clinical interpretive criteria for the SBT in serious infections (Stratton, 1988) Bacterial survival in the host is accompanied by the acquisition of different immune-evasive strategies. These strategies involve alteration of the bacterial surface, such as production of a capsule or immune-modulating membrane proteins, or secretion of soluble immune-evasion proteins, such as proteolytic factors. P.aeruginosa secretes a number of toxins and virulence factors, like elastase and alkaline protease (AprA) (Alexander et al., 2012)
Effect of serumonPseudomonas species:
Pseudomonas enzymes, especially elastase and alkaline protease, were shown to have direct effect on the serum hemolytic complement as a whole, and on the two recognition molecules of complement, C1q and C3 in particular(Alexander J. laarmen, et.al, 2012). Incubation of serum with 0-50 μg/ml elastase or protease (60 min, 37°C) resulted in a dose-dependent depletion of hemolytic complement with the protease being 3-4 times more efficient than elastase.A combination of the siderophores produced by Pseudomonasaeruginosa, pyochelin and pyoverdin, dramatically stimulates the growth of this bacterium in medium containing human transferrin. The amount of growth stimulation observed when each siderophore was added alone was only slightly less than the amount observed with the combination. Siderophoredefective mutants of strain PAO1 were isolated to test the effects of siderophore production on growth in transferrin and human serum(R Ankenbauer, et.al., 1985)
Effect of bacterial absorption on serum killing
The rate of intracellular bacterial lysis is largely controlled by the lysozyme concentration but complement is also necessary. Killing is closely related to complement concentration. Antibody is needed in such small amounts that it is rarely a limiting factor (Taylor, 1983) Both lysis and killing are stopped by bentonite absorption of serum and complete return to normal is not attained by subsequent addition of egg-white lysozyme. In a lysozymefree system lysis does occur after some delay probably due to the action of complement and antibody alone. In the presence of adequate complement and antibody the loss of complement (measured haemolytically) in bentonite treated serum is inadequate to account for the fall in bactericidal activity (Glynn and Milne, 1965 
Inhibitors of serum killing:
Investigation has shown that the complement-dependent bactericidal activity of normal human serum towards certain organisms requires magnesium ion, and also a serum euglobulin, properdin, which is distinct from antibody and complement (Pillemer.et.al., 1954; Wardlaw and Pillemer, 1956).The requirement for properdin was demonstrated by the loss of bactericidal activity following absorption of serum with the yeast cell-wall fraction 'zymosan'. The conditions of absorption were controlled so that properd in was removed without loss of component C'3. Properdin itself was eluted from the zymosan residue, and was able to restore bactericidal activity to properdin-deficient serum. The requirement for Mg ion was similarly demonstrated by the decrease in bactericidal activity following treatment of the serum with the cation ex-change resin Amberlite IRC-50 (sodium cycle). Addition of MgC1, restored bactericidal activity to resin-treated serum. The outer membrane constitutes the main barrier to the serum killing of gramnegative bacteria. Serum-resistant cells may be sensitized to the bactericidal action of serum by treatment with Tris and EDTA, a process known to lower the permeability barrier of the outer membrane by affecting the release of approximately half of the complexed lipopolysaccharide (It appears that serum resistance does not result from a block in the activation of the complement cascade. Rather, MACs formed on the surfaces of serum-resistant strains are not effectively inserted into the bacterial membranes and are released without causing lethal damage. 
Complement Role
In the late 19th century, Hans Ernst August Buchner found that blood serum contained a "factor" capable of killing bacteria. In 1894, Richard Pfeiffer, a German scientist, had discovered that when cholera bacteria were injected into the peritoneum of a guinea pig immunized against the infection, the pig would rapidly die. This bacteriolysis, Bordet discovered, did not occur when the bacteria was injected into a non-immunized guinea pig, but did so when the same animal received the antiserum from an immunized animal. Moreover, the bacteriolysis did not take place when the bacteria and the antiserum were mixed in a test tube unless fresh antiserum was used.
However, when Bordet heated the antiserum to 55 degrees centigrade, it lost its power to kill bacteria. Finding that he could restore the bacteriolytic power of the antiserum if he added a little fresh serum from a non immunized animal, Bordet concluded that the bacteria killing phenomenon was due to the combined action of two distinct substances, an antibody in the antiserum, which specifically acted against a particular kind of bacterium, and a non-specific substance, sensitive to heat, found in all animal serums, which Bordet called "alexine" (later named "complement").
The term "complement" was introduced by Paul Ehrlich in the late 1890s, according to him, the immune system consists of cells that have specific receptors on their surface to recognize antigens. Upon immunization with an antigen, more of these receptors are formed, and they are then shed from the cells to circulate in the blood. These receptors, which we now call "antibodies," were called by Ehrlich "amboceptors" to emphasize their bi-functional binding capacity: They recognize and bind to a specific antigen, but they also recognize and bind to the heat-labile antimicrobial component of fresh serum. Ehrlich, therefore, named this heat-labile component "complement," because it is something in the blood that "complements" the cells of the immune system.
There have been a number of studies which have examined the mechanism of serum killing of P.aeruginosa. Several investigators have presented evidence suggesting the importance of the classical complement pathway (CCP) activated by antibodies in the killing of some P.aeruginosa strains (Module Microbiology). Reports have stated that certain strains are killed by complement activated via the alternative complement pathway (ACP) in the apparent absence of antibodies, whereas others have suggested a role for both pathways. (Schiller 1987 ).
Flow Chart 1: Complement pathway
Resistance of P.aeruginosato killing by complement and evasion from neutrophils are major virulence traits that allow this organism to survive within the bloodstream and inflamedlung. To date, the actual mechanism for complement interaction on the P.aeruginosa surface is not well understood. 
Methodology

Collection of sample:
Samples collected from clinical laboratory, Hospitals totally 7 samples and transported in Stuart medium.
Isolation of pathogen:
The sample was serially diluted and plated onto nutrient agar plates, kept for incubation at 37°C for 24 hours.
Characterization of the Pseudomonas clinical isolate
A loopful of the inoculum from incubated nutrient agar plates was streaked on to selective media Pseudomonas isolation agar. 
Collection of serum sample for serological tests
The serum samples were collected from various hospitals and diagnostic laboratories in and around Chennai. Serum samples were collected from laboratory through lab technicians and stored in eppendorff and kept in ice. Totally 22 multiple aliquots of serum were prepared.
Elisa for anti Pseudomonas antibodies in human serum
3.5.1 P. aeruginosa antigen preparation for ELISA Human serum was screened for the presence of antipseudomonas antibodies using ELISA antibody capture technique. To capture the pseudomonas specific serum antibodies, two different whole cell antigenic preparations were made from three P. aeruginosa clinical isolates, Ps1, Ps2, Ps3.Protocol adopted for the generation of heat killed and formalin killed antigen to be used for antibody capture in ELISA is given in Flow Chart 2.
Flow Chart 2: P. aeruginosa antigen preparation for ELISA
P. aeruginosa ELISA
To screen a panel of human serum (n=20) for pseudomonas specific antibody (IgG), ELISA antibody capture technique was used with heat killed and formalin killed whole cell antigen preparations of 3 pseudomonas clinical isolate viz., Ps1, Ps2, Ps3. ELISA protocol is given in Flow Chart 3.
Flow Chart 3: P. aeruginosa ELISA
As there is no standard reference serum available to generate concentration vs OD 450 calibration curve, OD450 for each serum sample was used for comparative analysis. In order to normalize the impact of dilution on the overall antibody concentration in various serum samples, OD450 was converted and expressed as weighted average (WA) using the following formula: WA = (a1×d1, a2×d2… an×dn)/(d1, d2…dn) WA = Weighted average; a1=OD 450 for first dilution; d1 = dilution factor;  = Sum
Pseudomonas serum bactericidal assay
Serum bactericidal assay for pseudomonas was developed as described in the flow chart 4. Based on the ELISA observations, only two P. aeruginosa strains, Ps1 and Ps3 were tested for serum bactericidal activity against two positive and two negative human sera.
Flow Chart 4: P. aeruginosaSBA
Two important assay variables were included for optimization. The first variable is the target antibody ratio. While serum samples were diluted 2-fold from undiluted samples through 7 dilutions, the bacterial target was inoculated in 4 different counts, 50, 60, 70 and 80 CFU/well. The second important variable is the endogenous complement source that may contribute to the background killing of the target bacterium. This question was addressed by including a heat inactivated (56 o C for 30 min in a water bath) positive serum control. Inclusion of complement control served two purposes. While the complement control along with negative control gave as data to set the baseline (50% killing), it also enabled us monitor the target bacterium for direct complement inactivation in which case we would observe a flat line in killing with no serum dilution dependent variation in killing in comparison to C' control. Table 1 5. Discussion
The colonies from the nutrient agar plates were confirmed as Pseudomonas aeruginosa by selective media platting (Plate 1 -3) and biochemical tests (Table 1) .
Three Pseudomonas aeruginosa clinical isolates (Ps1, Ps2 and Ps3) were selected for antigen preparation. Heat and formalin killed antigen preparations were generated from these Pseudomonas isolates as described in the methodology. These whole cell antigen preparations were coated in the ELISA plate as capture antigens. Human sera (n=20) obtained from a clinical laboratory were screened for anti-pseudomonas antibodies (IgG) using these ELISA plates. Among the 20 test serum samples, three (TS-11, TS-14 and TS-16) were found to be reactive with both heat and formalin killed preparations of Ps1 (FIG 1) The primary objective of this research work is to develop a serum bactericidal assay (SBA) for the quantification of bactericidal antibodies in human serum for P. aeruginosa (pSBA). One of the critical variables in pSBA is the target (bacterial) ratio in the reaction. Hence, the bacterial inoculum was optimized according to the method described in the previous section with a positive and negative serum and the results presented in FIG 3 -4) . With the pSBA titer threshold set at 50% bacterial kill compared to complement control (without serum), the positive control reported a pSBA titer of 64-128 at 4 different inoculum load (~50, 60, 70, and 80 CFU/well) of Ps1. Similarly for Ps3, the positive control has returned a pSBA titer of 16 in all 4 inoculum load (FIG 4) .
Human serum contains endogenous complement that may contribute some background killing of the bacterium included in the assay mixture. This may not adversely affect the outcome of the assay as the serum gets diluted resulting in the endogenous complement also even if present. Nevertheless, the presence of endogenous may alter the assay background making it difficult to standardize. We tested the human serum (positive control) tested in pSBA for active endogenous complement by including a heat inactivated pair alongside the normal serum. As shown in  FIG 5 and 6 , the test sera have not exhibited any endogenous complement activity. This is evident with the disappearance of titer in the heat treated serum without exogenous complement compared to normal serum with exogenous complement. We anticipate the reappearance of bactericidal activity in the heat inactivated serum if supplemented with exogenous complement. This will be carried out in future studies. 
Summary and Conclusion
